DSIP

What it is

The story of its discovery sounds almost like science fiction. The Basel researchers Schoenenberger and Monnier induced deep sleep in rabbits by electrically stimulating the thalamus, obtained a substance from their cerebral venous blood and transferred it to other animals. In 1977 they described it as a peptide of nine amino acids and named it Delta Sleep-Inducing Peptide. Delta stands for the slow brain waves of deep sleep, the most restorative phase of the night.

In the double-blind experiments in 58 rabbits, only synthetic DSIP enhanced delta and spindle activity in the EEG, not its fragments or modified variants. A follow-up paper in 61 rabbits measured a mean increase in delta activity of 35 percent compared with the control animals. A 1984 review by Graf and Kastin summarized that DSIP mainly induces delta sleep in rabbits, rats, mice and humans, in cats rather REM sleep, and that the dose-response curve is U-shaped: too much works worse than the right amount.

How it is supposed to work

DSIP is not a sleeping pill in the classic sense. It is not supposed to knock you out, but to help the body find its way back into its own sleep rhythm. This is exactly what the first human study described: the participants felt sleep pressure, but showed no sedation of the kind known from sleeping pills in behavioral and EEG analyses. That is the difference from many sleeping pills, which force sleep but alter sleep architecture.

The second strand concerns the stress system. In humans, basal DSIP and cortisol levels are closely linked, and in a study of 12 patients with depression and 12 controls, DSIP responded differently to a stress hormone stimulus than in healthy people. The authors see this as a modulating role of DSIP in the stress hormone axis. In addition, there are reports of effects on pain, body temperature and daily rhythm. One peculiarity: DSIP is broken down very quickly in the body, but the described effect lasts longer. The common explanation is that DSIP provides a starting impulse rather than acting continuously.

Why deep sleep gets so much attention

A night runs in cycles of around 90 minutes in which light sleep, deep sleep and REM sleep alternate. Deep sleep occurs mainly in the first half of the night. In this phase the body releases growth hormone, tissue regenerates, and the brain flushes out metabolic waste via the so-called glymphatic system. With age, deep sleep decreases markedly, and many people feel less rested despite the same number of hours.

That is why a substance intended to promote delta sleep specifically is so appealing to people interested in longevity and recovery. For comparison with melatonin: melatonin is above all a timing signal and tells the body that it is night. DSIP, by contrast, is supposed to influence the depth of sleep. The two target different levers.

Who uses it and what is reported

Typical people interested in it are those with restless, shallow sleep, the highly stressed, shift workers and athletes who want to recover in deep sleep. In user circles, deeper, more restorative sleep without grogginess in the morning is reported. What is striking, however, is how inconsistent the reports are: some describe deeper sleep, a similarly large share notice nothing at all. These are anecdotal reports, not proof of efficacy.

DSIP is used as an injection under the skin in the evening, usually in courses lasting a few weeks. We do not give a dosage, because DSIP is not an approved medicine. And no peptide replaces the basics: a dark, cool room, fixed sleep times, less screen time in the evening and no caffeine in the afternoon.

What the studies show

Schneider-Helmert et al. 1981 — the first human study

6 healthy volunteers, four men and two women, double-blind in a crossover design against placebo. Sleep time increased by 59 percent within 130 minutes after administration; in the following night, sleep onset latency shortened and sleep efficiency increased. Elaborate EEG and behavioral analyses showed no classic sedation. No side effects were observed.

Schneider-Helmert 1987 — chronic insomnia over 7 nights

14 middle-aged people with severe chronic insomnia, double-blind and placebo-controlled, sleep lab with polysomnography. Night-time sleep improved with the first administration and further with the following ones, sleep efficiency reached the level of healthy comparison subjects, and attention and performance during the day increased significantly.

Monti et al. 1987 and Bes et al. 1992 — the independent follow-up studies

Monti tested DSIP double-blind in a crossover over 4 nights in chronic insomnia. More sleep occurred only in light sleep stage 2, and this difference already existed before treatment; deep sleep and REM sleep remained unchanged. Bes studied 16 insomniacs double-blind in parallel groups over 3 treatment nights. Sleep efficiency and sleep onset latency improved slightly, but the authors considered the effects weak and partly a chance fluctuation in the placebo group. Both concluded that the clinical benefit is small.

Where the data stop

The controlled human studies are small, with 6, 14 and 16 participants, short, with 3 to 7 treatment nights, and date from 1981 to 1992. The positive results come from the discoverers’ circle; the two independent studies found no clinically meaningful effect. Of all things, deep sleep, to which DSIP owes its name, did not change in insomniacs. No modern study followed after that, and there is no approval anywhere.

The fundamentals are also open. The gene, precursor protein and receptor of DSIP were never found; a 2006 review therefore calls the sleep factor hypothesis extremely poorly documented. In rats, more stable modifications promoted sleep, DSIP itself did not, presumably because it is broken down too quickly. In patients with Cushing’s syndrome, more DSIP in the blood was even associated with less deep sleep. The findings on withdrawal and pain come from case series without a control group: 67 withdrawal patients, of whom 49 could be evaluated and 48 benefited, and 7 pain patients, of whom 6 had less pain. These are indications, not proof.

Status, approval and legal

DSIP is not approved as a medicine in Germany or the EU and is distributed as a research peptide via the gray market. Purity and content are therefore entirely up to the seller; there is no independent control. On July 23–24, 2026, an FDA expert panel discussed whether DSIP should be permitted for compounded medicines in the US. The FDA’s experts advised against it, and the panel also voted against it by majority (6 in favor, 7 against, 1 abstention). An FDA decision is pending. As a matter of principle, we do not give dosage information for unapproved substances. No reliable source could be found on doping relevance, so nothing is said about it here.

Safety

In the small studies of the 1980s, DSIP was well tolerated: in the first human study no side effects occurred, in the withdrawal series no major ones. In user reports, a reaction at the injection site is mentioned most often. A systematic safety assessment by today’s standards and long-term data are completely lacking, as are data on pregnancy, breastfeeding and interactions with sleeping pills or sedatives. Anyone suffering from persistent insomnia should have the cause clarified by a physician before turning to a gray-market peptide.

Sources

• Schoenenberger & Monnier, PNAS 1977
• Schoenenberger et al., Pflügers Archiv 1978
• Schneider-Helmert et al., International Journal of Clinical Pharmacology 1981
• Graf & Kastin, Neuroscience & Biobehavioral Reviews 1984
• Schneider-Helmert, European Neurology 1987
• Monti et al., International Journal of Clinical Pharmacology Research 1987
• Bes et al., Neuropsychobiology 1992
• Dick et al., Neuropsychobiology 1983
• Kovalzon & Strekalova, Journal of Neurochemistry 2006
• Friedman et al., Neuroendocrinology 1994
• McDermott (law firm), report on the FDA compounding panel meeting of July 23–24, 2026